Stockscreener 앱 받기
10.10
4.03%
-0.44
시간 외 거래:
10.10
전일 마감가:
$10.54
열려 있는:
$10.56
하루 거래량:
244.58K
Relative Volume:
0.96
시가총액:
$459.09M
수익:
$84.82M
순이익/손실:
$-21.43M
주가수익비율:
-11.35
EPS:
-0.89
순현금흐름:
$-27.23M
1주 성능:
-12.73%
1개월 성능:
-30.53%
6개월 성능:
-19.47%
1년 성능:
+92.30%
1일 변동 폭
$9.847
$10.91
1주일 범위
$9.847
$11.65
52주 변동 폭
$5.29
$20.90
Y Mabs Therapeutics Inc Stock (YMAB) Company Profile
명칭
Y Mabs Therapeutics Inc
전화
212-847-9841
주소
230 PARK AVENUE, NEW YORK, NY
YMAB을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
| YMAB | 10.10 | 459.09M | 84.82M | -21.43M | -27.23M | -0.89 |
| VRTX | 450.37 | 115.43B | 10.63B | -479.80M | -1.35B | 13.33 |
| REGN | 744.50 | 82.04B | 13.85B | 4.65B | 3.32B | 35.06 |
| ARGX | 596.74 | 35.30B | 1.86B | -40.29M | -1.28B | -4.16 |
| ALNY | 246.80 | 32.04B | 2.09B | -332.26M | 16.06M | -4.14 |
| BNTX | 108.23 | 24.89B | 3.30B | -501.07M | 1.03B | 11.54 |
Y Mabs Therapeutics Inc Stock (YMAB) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-08-16 | 개시 | Cantor Fitzgerald | Overweight |
| 2024-06-28 | 개시 | Truist | Buy |
| 2023-05-10 | 업그레이드 | Wedbush | Neutral → Outperform |
| 2023-04-03 | 다운그레이드 | Guggenheim | Buy → Neutral |
| 2023-01-27 | 다운그레이드 | Morgan Stanley | Equal-Weight → Underweight |
| 2023-01-05 | 다운그레이드 | Cowen | Outperform → Market Perform |
| 2022-12-02 | 다운그레이드 | BofA Securities | Buy → Neutral |
| 2022-10-31 | 다운그레이드 | JP Morgan | Neutral → Underweight |
| 2022-10-31 | 다운그레이드 | Wedbush | Outperform → Neutral |
| 2022-07-06 | 재개 | Canaccord Genuity | Buy |
| 2022-06-24 | 개시 | BMO Capital Markets | Outperform |
| 2022-02-03 | 재개 | Guggenheim | Buy |
| 2021-11-19 | 재개 | Morgan Stanley | Equal-Weight |
| 2021-11-16 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2021-05-07 | 업그레이드 | BofA Securities | Neutral → Buy |
| 2021-04-23 | 재개 | Cowen | Outperform |
| 2021-03-22 | 재개 | JP Morgan | Overweight |
| 2021-01-15 | 다운그레이드 | BofA Securities | Buy → Neutral |
| 2020-11-09 | 재확인 | H.C. Wainwright | Buy |
| 2020-05-05 | 개시 | Barclays | Overweight |
| 2020-05-01 | 개시 | Janney | Buy |
| 2020-04-29 | 개시 | Morgan Stanley | Equal-Weight |
| 2019-12-24 | 개시 | JP Morgan | Overweight |
| 2019-11-20 | 개시 | Guggenheim | Buy |
| 2019-09-04 | 개시 | Wedbush | Outperform |
| 2019-04-01 | 개시 | H.C. Wainwright | Buy |
| 2018-10-16 | 개시 | BTIG Research | Buy |
| 2018-10-16 | 개시 | BofA/Merrill | Buy |
모두보기
Y Mabs Therapeutics Inc 주식(YMAB)의 최신 뉴스
Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Given Consensus Rating of "Moderate Buy" by Brokerages - MarketBeat
Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Q3 2024 Earnings Call Transcript - MSN
Oppenheimer Begins Coverage on Y-mAbs Therapeutics (NASDAQ:YMAB) - Defense World
Y-mAbs started at outperform at Oppenheimer on pre-targeted radiotherapies - MSN
The Market Doesn't Like What It Sees From Y-mAbs Therapeutics, Inc.'s (NASDAQ:YMAB) Revenues Yet As Shares Tumble 26% - Simply Wall St
Brain Cancer Treatment Market Growth Overview Future - openPR
Y-mAbs Therapeutics (NASDAQ:YMAB) Now Covered by Analysts at Oppenheimer - MarketBeat
Beyond The Numbers: 4 Analysts Discuss Y-mAbs Therapeutics Stock - Benzinga
Institutional investors in Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) lost 25% last week but have reaped the benefits of longer-term growth - Yahoo Finance
HC Wainwright Reaffirms Buy Rating for Y-mAbs Therapeutics (NASDAQ:YMAB) - Defense World
Y-mAbs Therapeutics' (YMAB) Buy Rating Reaffirmed at HC Wainwright - MarketBeat
Trading (YMAB) With Integrated Risk Controls - Stock Traders Daily
YMAB FY2024 EPS Forecast Increased by Cantor Fitzgerald - Defense World
Asia Deal Watch: Apollo Takes A Shine To Chinese Biotech’s Cardiometabolic Candidate - Scrip
Cantor Fitzgerald Issues Positive Outlook for YMAB Earnings - MarketBeat
Investors might be losing patience for Y-mAbs Therapeutics' (NASDAQ:YMAB) increasing losses, as stock sheds 13% over the past week - Simply Wall St
Leptomeningeal Metastases Clinical Trials 2024: FDA - openPR
Y-mAbs Therapeutics Reports Third Quarter 2024 Financial Results and Recent Corporate DevelopmentsY-mAbs Therapeutics, a biopharmaceutical company focusing on innovative radioimmunotherapy and antibody-based products for cancer treatment, rec - Defense World
Y-mAbs Therapeutics (NASDAQ:YMAB) Shares Gap Down After Earnings Miss - Defense World
Earnings call: Y-mAbs Therapeutics reports Q3 2024 financials - Investing.com India
Y-mAbs Therapeutics, Inc. (YMAB) Reports Q3 Loss, Lags Revenue Estimates - MSN
Y-mAbs Therapeutics (NASDAQ:YMAB) Issues Earnings Results, Misses Estimates By $0.02 EPS - MarketBeat
Y-mAbs Therapeutics Inc (YMAB) Q3 2024 Earnings Call Highlights: Navigating Revenue Challenges ... By GuruFocus - Investing.com Canada
Y-mAbs Therapeutics Inc (YMAB) Quarterly 10-Q Report - Quartzy
Y-mAbs Reports Third Quarter 2024 Financial Results - TipRanks
Y-mAbs Therapeutics (NASDAQ:YMAB) Shares Gap DownShould You Sell? - MarketBeat
Y-mAbs Therapeutics, Inc. Reiterates Earnings Guidance for the Year 2024 - Marketscreener.com
Y mAbs Therapeutics earnings missed by $0.01, revenue fell short of estimates - Investing.com Canada
Y-mAbs Therapeutics Inc Reports Q3 2024 Revenue of $18.5 Million - GuruFocus.com
Y-mAbs Reports Third Quarter 2024 Financial Results and Recent Corporate Developments - The Manila Times
Y-mAbs Q3 Revenue Falls 10%, But Secures Key Japan Deal and Patent Extension | YMAB Stock News - StockTitan
Examining the Future: Y-mAbs Therapeutics's Earnings Outlook - Benzinga
What To Expect From Y-mAbs Therapeutics Inc (YMAB) Q3 2024 Earni - GuruFocus.com
What To Expect From Y-mAbs Therapeutics Inc (YMAB) Q3 2024 Earnings - Yahoo Finance
Exclusive License Agreement Between Y-mAbs Therapeutics, Inc. and Nobelpharma Co., Ltd. for Development and Commercialization of DANYELZA(R) in Japan - Defense World
(YMAB) Trading Advice - Stock Traders Daily
Vanguard Group Inc's Strategic Acquisition in Y-mAbs Therapeutics Inc - GuruFocus.com
Y-mAbs enters Japan market with Nobelpharma for cancer therapy By Investing.com - Investing.com Canada
Y-mAbs enters Japan market with Nobelpharma for cancer therapy - Investing.com
Y-mAbs and Nobelpharma Announce Exclusive License and Distribution Agreement for DANYELZA® (naxitamab-gqgk) in Japan - The Manila Times
Vir Biotechnology, Inc. (VIR) Reports Q3 Loss, Lags Revenue Estimates - MSN
Will Y-mAbs Therapeutics, Inc. (YMAB) Report Negative Earnings Next Week? What You Should Know - MSN
Y-mAbs Therapeutics (YMAB) Scheduled to Post Quarterly Earnings on Friday - Defense World
Y-mAbs Therapeutics (YMAB) Scheduled to Post Earnings on Friday - MarketBeat
Positive Outlook For Novartis As Company Capitalizes On Growing Treatment Opportunities, Analyst Highlights - Benzinga
Y-mAbs Therapeutics Investors Get Final OK For $19.7M Deal - Law360
Leptomeningeal Metastases Market to Show Remarkable Growth Trends from 2024 to 2034, DelveInsight Reports | Y-mAbs Therapeutics, Plus Therapeutics, AngioChem, AstraZeneca - The Globe and Mail
Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Given Consensus Rating of "Moderate Buy" by Analysts - MarketBeat
Objective long/short (YMAB) Report - Stock Traders Daily
Y-mAbs Announces Third Quarter 2024 Conference Call and Webcast - The Manila Times
Y-Mabs Therapeutics Inc (YMAB-Q) QuotePress Release - The Globe and Mail
Y Mabs Therapeutics Inc (YMAB) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.93%
3.56%
자본화:
|
볼륨(24시간):